Polymyxins - A review focusing on their nephrotoxicity

Revista da Associacao Medica Brasileira

Volumn 55, Issue 6, 2009, Pages 752-758

  Mendes, Carlos Alberto Caldeira ^a   Burdmann, Emmanuel A ^b  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute renal failure; Colistin; Nephrotoxicity; Polymyxin B.

Indexed keywords

ANTIINFECTIVE AGENT; POLYMYXIN;

ACUTE KIDNEY FAILURE; ANIMAL; CHEMICALLY INDUCED DISORDER; DOG; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY; MULTIDRUG RESISTANCE; REVIEW;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-BACTERIAL AGENTS; DOGS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY; POLYMYXINS;

EID: 77649153850     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0104-42302009000600023     Document Type: Article

References (57)

1. Moyer JH, Mills LC, Yow EM. Toxicity of polymyxin B. I. Animal studies with particular reference to evaluation of renal function. Arch Intern Med. 1953; 92:238-47.
2. Falagas EM, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40:1333-41.
3. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance program (2001-2004). Clin Microbiol Infect. 2006; 12:315-21.
4. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Ann. Rev Biochem. 1977; 46:723-63.
5. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J. Antimicrob Chemother. 2007; 60:78-82.
6. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michaloupoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005; 8:24
7. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004; 54:566-9.
8. Vinnicombe J, Stamey TA. The relative nephrotoxicities of polymyxin B sulfate, sodium sulfomethyl-polymyxin B, sodium sulfomethyl-colistin (colimycin), and neomycin sulfate. Invest Urol. 1969; 6:505-19.
9. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006; 50:1953-8.
10. Cooperstock M. Inativaction of endotoxin by Polymyxin B. Antimicrob Agents Chemother. 1974; 6:422-5.
11. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003; 7:108-14.
12. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005; 23:400-5.
13. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of recent literature. Clin Med Res. 2006; 4:138-46.
14. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolledy study. Clin Ther. 2008; 30:143-51.
15. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008; 60:163-7.
16. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005; 49:3624-30.
17. Product information. Polymyxin B sulfate sterile, 500,000 units, Bedfordpoly B. Bedford. Ohio: Bem Venue Bedford Laboratories; February 2004.
18. Hoeprich PD. The polymyxins. Med Clin North Am. 1970; 54:1257-65.
19. Colestimetato de Sódio (Coly-Mycin M)/ FDA: Information for Healthcare Professionals Colistimethate (Coly-Mycin M and generic products). Rockville: Food and Drug Administration; 2007. [cited 2007 jun 28]. Available from: URL:http://www.fda.gov/cder/drug/InfoSheets/HCP/colistimethateHCP.htm.
20. Li J, Rayner CR, Nation RL. Colistin-associated acute renal failure: revisited. South Med J. 2005; 98:1229-30.
21. Sarria JC, Angulo-Pernett F, Kimbrough RC, McVay CS, Vidal AM. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis. 2004; 23:340-341.
22. Fass RJ, Barnishan J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother. 1995; 36:343-53.
23. Levin AS, Mendes CM, Sinto SI, Sader, HS, Scarpitta CR, Rodrigues E, et al. An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil. Infect. Control Hosp. Epidemiol. 1996; 17:366-8.
24. Dalla-Costa LM, Coelho JM, Souza HÁ, Castro ME, Stier CJ, Bragagnolo KL, et al. Outbreak of Carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. Clin Microbiol. 2003; 41:3403-6.
25. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother. 1999; 33:960-7.
26. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006; 10:R27
27. Kazy Z, Puhó E, Czeizel AE. Parenteral polymyxin B treatment during pregnancy. Reprod Toxicol. 2005; 20:181-2.
28. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med. 1962; 266:759-62.
29. Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med. 1968; 68:318-27.
30. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 curses of therapy. Ann Intern Med. 1970; 72:857-68.
31. Beirne GJ, Hansing CE, Octaviano GN, Burns RO. Acute renal failure caused by hypersensitivity to polymyxin B sulfate. JAMA. 1967; 202:156-8.
32. Kallel H, Hamida CB, Ksibi H, Bahloul M, Hergafi L, Chaari A, et al. Suspected acute interstitial nephritis induced by colistin. J Nephrol. 2005; 18:323-6.
33. Nord NM, Hoeprich PD. Polymyxin B and colistin: a critical comparison. N Engl J Med. 1964; 270:1030-5.
34. Yow EM, Moyer JH. Toxicity of Polymyxin B. II. Human studies with particular reference to evaluation of renal function. Arch Intern Med. 1953; 92:248-57.
35. Price DJ, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J. 1970; 4:525-7.
36. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J. 1998; 12:592-4.
37. Conway SP, Etherington C, Munday J, Goldman MH, Strong JJ, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacer bations in adults with cystic fibrosis. Ann Pharmacother. 2000; 34:1238-42.
38. Reed MD, Stern C, O'Riordan MA, Blumer JL. The pharmacokinetic of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001; 41:645-54.
39. Levin AS, Barone AA, Penco J, Santos V, Narinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999; 28:1008-11.
40. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005; 5:1.
41. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents. 2005; 26:504-7.
42. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combinations therapy with intravenous colistin for management of infections due multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005; 49:3136-46.
43. Michelopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005; 11:115-21.
44. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents. 2006; 28:366-9.
45. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis. 2007; 11:402-6.
46. Fica CA, Céspedes JI, Gompertz GM, Jalón VM, Sakurada ZA, Sáez LE. Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli (Colistin en infecciones nosocomiales por bacilos gram negativos pan-resistentes). Rev Chilena Infectol. 2007; 24:360-7.
47. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008; 61:417-20.
48. Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect. 2008; 56:185-90.
49. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother. 2003; 47:2659-62.
50. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006; 40:1939-45.
51. Furtado GH, dAzevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007; 30:315-9.
52. Pastewski AA, Caruso P, Parris AR, Dizon R, Kopec R, Sharma S, et al.Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother. 2008; 42:1177-87.
53. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003; 36:1111-8.
54. Reina R, Estenssoro E., Saenz G, Canales H S, Gonzalvo R, Vidal G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005; 31:1058-65.
55. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007; 33:1162-7.
56. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007; 51:1905-11.
57. Oliveira MS, Prado GVB, Costa SF, Grimbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008; 61:1369-75.